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Home nocturnal hemodialysis (HNHD) is cost-effective
relative to in-center hemodialysis (IHD) in short-run analyses.
The effect in long-run analyses, when technique failures,
declining benefits, delayed training, transplantation and
death are considered, is unknown. We used decision analysis
techniques to examine the relative cost-effectiveness of
HNHD and IHD, projecting future costs and health effects
over a lifetime with end-stage renal disease. We developed a
Markov state-transition model comparing two strategies:
only IHD or starting on IHD and subsequently transferring to
HNHD. The model incorporates transplantation. In the base
case, half the population was eligible for transplantation,
with 13 of grafts from live donors. The time to transplant was
0.75 years for live and 5 years for deceased donor
transplants. The delay before initiation of HNHD was 5 years.
Costs and outcomes were discounted at 3% per annum.
Model parameters were derived from a literature review. We
also conducted one-way sensitivity analyses and Monte Carlo
simulations. The HNHD strategy was associated with a
quality-adjusted survival estimate of 5.79 quality-adjusted life
years (QALYs), with lifetime costs of $538 094. The values for
IHD were 5.31 QALYs and $543 602, respectively. Thus, HNHD
is cost saving while improving quality of life. The incremental
cost–utility ratio was consistently less than $50 000 per
QALY in sensitivity and Monte Carlo analyses. Important
determinants of cost-effectiveness were transplantation
time and whether benefits declined over time. Our model
suggests that HNHD improves quality-adjusted survival over
IHD at an economically attractive cost–effectiveness ratio.
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End-stage renal disease (ESRD) is a potentially devastating
illness that can reduce the length and the quality of a person’s
life.1–6 Mortality rates for individuals with ESRD are 20 times
higher than for the general population,7 and the average
quality of life on dialysis has been reported as similar to that
seen in people with hepatocellular carcinoma.8 The treatment
of choice for ESRD is renal transplantation,9 which improves
length and quality of life.10–13 Unfortunately, the supply of
kidneys for transplantation is less than the demand. For many,
dialysis will be the only therapy for ESRD, thereby mandating
attention to methods of improving quality of life on dialysis.
In 1993, a program was developed in Toronto offering
home nocturnal hemodialysis (HNHD). This technique
combined prior innovations such as more frequent treat-
ments,14 long dialysis times15,16 and treatment in the home.17
The HNHD method as practiced in Toronto involves five to
seven home-based treatments a week, with the patient
dialyzing for 6–8 h overnight as they sleep. Previous research
by our group has demonstrated in a 1-year analysis that
HNHD is less expensive than hospital-based in-center
hemodialysis (IHD). Furthermore, patients performing
HNHD have a quality of life that is significantly higher than
that of those performing IHD and similar to that of those who
have received a kidney transplant,18,19 making it an economic-
ally dominant therapy (both cost saving and more effective).
While the benefits of HNHD have been demonstrated
prospectively in prevalent dialysis patients who remain on
their original dialysis modality, the impact of HNHD over a
long-run analysis is uncertain. Cross-sectional and prospec-
tive cohort analyses may overestimate both cost savings and
health benefits for four reasons. First, short-run studies may
exclude HNHD patients who fail the modality and return to
IHD, or those who receive a kidney transplant, which also
reduces costs and improves length and quality of life.10–13
Such considerations are particularly important when the time
to transplantation is short (e.g., when a live donor is
available, or when the patient has been on the transplant
waiting list for many years). Second, short-run analyses may
be inaccurate when benefits decline over time, costs rise over
time or when there are large initial expenses (such as capital
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and training costs) that are realized when the patient starts
on the modality, with savings accruing later. Third, as the
number of centers that perform HNHD is small, the
generalizability of these results has not been confirmed.
Fourth, a critical assumption of short-run studies is that the
quality of life of a patient who is transferred from IHD to
HNHD will rise to the level of an HNHD patient in our
cross-sectional study, an assumption that has not been
prospectively tested.
These deficiencies lead to five important questions. What
is the impact of HNHD over a lifetime of ESRD therapy?
Does the delay before training a patient for HNHD reduce
cost-effectiveness? How long must a patient perform HNHD
before the modality is cost-effective? What if costs and
benefits change over time? What if there is a delay from the
start of HNHD until the benefits are realized? A prospective
cohort study that followed patients on IHD and HNHD over
their lifetimes could answer these questions; however, timing
and funding issues make this an impractical choice. Herein,
we provide a decision analysis model that estimates the cost-
effectiveness of HNHD over a lifetime of ESRD. The deci-
sion analysis model also identifies parameters that impact on
cost-effectiveness and merit priority in clinical trials. This
information would be especially useful to health-care payers
who are considering funding for HNHD programs.
RESULTS
Reference case analysis
For the reference case, our model estimated that the
remaining life expectancy would be 13.4 years if the patient
was treated with HNHD and 13.2 years if treated with IHD.
As we assumed an identical mortality rate on dialysis for both
groups, this small difference in overall survival related to a
higher rate of complications on dialysis for IHD. After
applying quality of life weights and discounting, the health
benefits associated with HNHD and IHD were 5.79 and 5.31
quality-adjusted life year (QALYs), respectively. The corres-
ponding discounted costs were $538 094 and $543 602. That
is, HNHD was 9.0% more effective, producing 0.48 more
QALYs while saving $5508, or about 1.0% of total health
expenses, and was the economically dominant option. The
net monetary benefit (NMB) was positive and favored
HNHD across the tested range of l (Table 1).
Scenario analyses
What if a patient was ineligible for transplant? When
transplantation was not modeled, HNHD produced 0.47
more QALYs while saving $6841. HNHD was dominant and
the NMB favored HNHD across the tested range of l
(Table 1).
What if HNHD was selected as the initial dialysis modality
for a patient with ESRD? In this scenario, HNHD generated
0.99 more QALYs, while reducing costs by $9118. Again,
HNHD was dominant with a positive NMB across the tested
range of l (Table 1).
What if there is a delay between the start of HNHD and
when the improvements in quality of life associated with
HNHD are realized? When modeling the improvement in
utility for HNHD as a linear function over time, HNHD was
the dominant modality even when the time to full HNHD
utility was longer than 20 years.
Finally, we examined the impact of quality of life
improvements and cost savings that declined over time, such
that eventually HNHD and IHD had equivalent costs and
Table 1 | Results of primary and scenario-based analyses from a decision analysis examining the cost-effectiveness of HNDH
Net monetary benefit at cost–effectiveness ceiling
QALYs generated Cost accrued
Incremental cost–
effectiveness ratio $0 $50 000 $100 000
Reference case analysis
IHD 5.31 $543 602 $11 475 $5508 $29 508 $53 508
HNHD 5.79 $538 094
Difference (HNHDIHD) 0.48 $5 508
Transplant not allowed scenario
IHD 2.78 $370 047 $14 555 $6841 $30 341 $53 841
HNHD 3.25 $363 206
Difference (HNHDIHD) 0.47 $6 841
HNHD as initial dialysis modality scenario
IHD 5.31 $543 602 $9210 $9118 $58 618 $108 118
HNHD 6.30 $534 484
Difference (HNHDIHD) 0.99 $9 118
Initial HNHD without transplantation scenario
IHD 5.48 $730 590 $21 800 $37 932 $124 932 $211 932
HNHD 7.22 $692 658
Difference (HNHDIHD) 1.74 $37 932
QALYs=quality-adjusted life years; IHD=in-center hemodialysis; HNHD=home nocturnal hemodialysis.
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effectiveness. When the differences in both costs and utility
declined linearly over time, HNHD was not cost-effective
(l¼ $50 000/QALY) when the time until the costs and
benefits were equivalent was less than 4 years. The model was
not sensitive to costs and utility that declined individually.
Sensitivity analyses
HNHD was no longer cost-effective if IHD was less expensive
than HNHD (i.e. annual IHD cost less than $57 000), if
HNHD was more expensive than IHD (i.e. annual HNHD
cost more than $75 000) or if the utility score was higher for
IHD. A shorter time to HNHD training improved the cost-
effectiveness of HNHD; however, HNHD remained the
economically dominant option even with extremely long
delays (440 years). HNHD was cost-effective unless the time
to deceased or live donor transplant was less than 108 weeks.
The model was not sensitive to post-transplant variables.
We performed 1000 iterations of the model in the Monte
Carlo analysis (Figure 1). The estimated lifetime health-
care costs were $551 3247$99 766 for IHD and
$544 5647$96 878 for HNHD. The estimated number of
QALYs generated over a lifetime of ESRD by IHD was
5.3471.24, and by HNHD was 5.8671.26. HNHD was
dominant in 75.9% of iterations, and cost-effective
(l¼ $50 000/QALY) in 99.7% of iterations. Figure 2 illus-
trates an acceptability curve based on the Monte Carlo data
graphing the probability that HNHD is cost-effective across a
wide range of possible values for the societal maximum
willingness to pay for a QALY.
DISCUSSION
Our previous work demonstrated that HNHD is cost-
effective in prevalent dialysis patients. This study explored
the cost-effectiveness of HNHD over a lifetime of renal
replacement therapy to address questions that have not been
answered in clinical trials to date. This model found that
HNHD remained the dominant therapy in a long-run
analysis, despite the design of our analysis that deliberately
biased the model against HNHD. For example, based on our
previous studies, we selected for our reference case an average
5-year delay before switching from IHD to HNHD, a period
similar to the average time to transplant. As a result, less than
half of the patients in the HNHD strategy of our reference
analysis ever transfer to that form of dialysis. To provide
another example, we assumed that home and conventional
hemodialysis patients have the same mortality rate, although
some data suggest that home dialysis patients may have better
longevity.20 We also assumed that many of the known health
benefits of HNHD (such as better blood pressure control) do
not directly lead to cost savings. Finally, we did not allow for
the capital costs of HNHD to be amortized over long periods
of time, and assumed that in-center facilities were already in
existence and IHD capital costs included only new dialysis
machines. Even with these features, our findings were robust,
with our model broadly favoring HNHD in sensitivity
analyses. The Monte Carlo analysis also showed the super-
iority of HNHD, and is likely the most compelling analysis as
it accounts for the range and distribution of uncertainty in
the model. However, HNHD was economically unattractive if
the costs of IHD were less than HNHD, if IHD was associated
with a higher quality of life or if the benefits of HNHD
declined rapidly.
When compared to our previous 1-year study,18,19 this long-
run analysis predicts cost savings and utility gains that are less
in relative and absolute terms, but still clinically significant.21,22
It is likely that the economic advantage of HNHD is less over
long-run analyses (which account for training delays, patient
death and transplantation) than predicted in cross-sectional or
short-run studies. At this time, there is insufficient clinical trial
data to allow modeling comparisons between HNHD and
peritoneal dialysis or intensive forms of hemodialysis such as
short daily hemodialysis.
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Figure 1 | Scatter plot of cost and effectiveness differences
between home nocturnal (HNHD) and in-center hemodialysis
(IHD) from 1000 iterations of a second-order Monte Carlo
decision analysis model.
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Figure 2 | Cost–effectiveness acceptability curve based on results
from 1000 iterations of a second-order Monte Carlo decision
analysis examining the cost-effectiveness of home nocturnal
hemodialysis (HNHD).
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Our model assumed that all capital costs for HNHD are
borne at the initiation of the modality, with cost savings
accruing over subsequent years. For this reason, changes in
any parameter that allows patients to stay on HNHD longer
improved the cost-effectiveness of this therapy. For example, a
shorter time to HNHD training and a lower HNHD
technique failure rate improved the cost-effectiveness of
HNHD. As transplantation has similar effectiveness to HNHD
but lower costs, transplantation has the effect of reducing the
advantages of HNHD over IHD. Consequently, changes in
parameters that reduced access to transplantation advantaged
HNHD. For example, longer transplant wait times (including
lower access to live donors) and lower proportions of
transplant eligibility improved the cost-effectiveness of
HNHD. Allowing HNHD capital costs to be amortized over
5 years substantially improved the cost-effectiveness of
HNHD. Our model suggests that HNHD is no longer cost-
effective if the time from HNHD training to renal transplant
is less than 2 years (e.g. in jurisdictions with short cadaveric
wait times, or when a potential live kidney donor is available).
While clinicians may still opt to place patients on HNHD in
these cases, they should be aware of the potential negative
economic impact. This emphasizes the need to identify
appropriate HNHD candidates as early as possible.
A weakness of this model relates to the uncertainty in
some of the key parameters, such as the utility of HNHD. The
cost of HNHD and quality of life while on this modality were
estimated from relatively small studies that were not
randomized. It is possible that a randomized trial could
negate the findings of this model and its supporting trials.
Additionally, the values for some model parameters (e.g. graft
and patient survival) were derived from unselected cohorts
with characteristics different from our simulated cohort.
Further research is needed to examine the costs and utility of
IHD or HNHD, preferably in a prospective randomized
manner. In addition, a decision analysis model is, by
necessity, a simplified view of the states of health experienced
by individuals. While we have modeled the major health
states an individual with ESRD would experience (dialysis,
transplantation, hospitalization and death), it is possible that
the structure of our model does not sufficiently reflect the
complexities of the lives of people with ESRD, and thus our
results do not accurately reflect the reality of life with kidney
disease. For example, we did not model the impact of renal
disease on family members. The cohort that we have modeled
is similar to those HNHD patients that have been studied in
clinical trials; however, these patients are systematically
different from the ‘average’ hemodialysis patient. Patients
in HNHD studies to date tend to be younger, educated and
less likely to have diabetes or cardiac disease. Psychological
parameters such as self-motivation may also be different in
studied HNHD patients. Also, by definition, patients in
HNHD studies have had access to an HNHD program. For
these reasons, the results of previous clinical trials and this
decision analysis should not be generalized to the broader
hemodialysis population. Finally, our modeled cohort was
based on studies of prevalent dialysis patients, introducing
the possibility of survivorship bias. For example, patients
who trained on HNHD but failed and returned to IHD or
suffered an early death would not have been represented in
the cost–utility trials performed to date, and could have
higher health-care costs and lower utility scores. Inclusion of
these patients would have a tendency to reduce the benefits of
HNHD. We have allowed HNHD failure in our model;
however, this does not eliminate potential survivorship bias.
This study suggests that HNHD is a long-term cost-effective
addition to the therapeutic options for ESRD. This conclusion
is robust and consistent over a wide range of sensitivity
analyses; however, no large-scale randomized trials have been
carried out in this area. Further modeling may be required in
the future as additional clinical trial data become available.
MATERIALS AND METHODS
Model overview
A Markov state transition decision analysis model was created to
evaluate the projected outcomes over a lifetime of ESRD therapies,
with and without HNHD, allowing for modality change, transplant-
ation and patient death. The model was constructed in Data Pro
release 10 (TreeAge Software Inc., Williamstown, MA, USA).
Markov-based decision analysis models represent an illness as a
series of discrete states, with the transitions between these states
representing the progression of the disease. Markov models are
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useful because they show how a disease evolves over time. Our
model compared the outcomes when a patient receives only IHD as
their form of dialysis, versus starting on IHD and subsequently
transferring to HNHD. Live and deceased donor transplantations
were also modeled for both groups. The start time of the model (i.e.
time zero) is the first day of renal replacement therapy. One-way
sensitivity analyses and Monte Carlo simulations were used to test
the effect of uncertainty in the model. Our analysis followed the
recommendations of the Panel on Cost-Effectiveness in Health and
Medicine,23 with the exception of the study perspective, which was
that of the health-care payer. This was the perspective taken in the
studies used as the basis of the cost estimates in this model. It is
possible that broader perspectives, such as the societal perspective,
which take into account items such as productivity effects, may
produce different estimates of the economic impact of various forms
of dialysis; however, little data of this type are available at this time.
Supplementary material accompanying this manuscript provides
further details regarding the model’s structure (See Appendix S1).
Costs and effectiveness
In this study, QALYs were taken as the measure of effectiveness of
dialysis. We calculated QALYs by multiplying the utility of a
particular health state by the duration spent in the state. Utilities
represent patient preferences for health states, and are ranked on a
continuous scale between 0.0 (a quality of life equivalent to death)
and 1.0 (the best possible quality of life). Costs were determined
from the perspective of the health-care payer (such as a provincial
Ministry of Health or HMO), and converted to year 2003 Canadian
dollars. Costs not described in the model (such as treatments for
conditions unrelated to ESRD) were assumed to be equal in both
groups. This biases the model against HNHD, as we assumed that
many of the benefits of HNHD (such as improvements in cardiac
function and sleep apnea) could not lead to direct cost savings in
our model, although they may contribute to the higher utility scores
and lower hospitalization modeled for HNHD. The base estimates
for costs and utility were taken from our previously published
prospective studies, with ranges for testing in sensitivity analyses
taken from a broader literature review.12,18,19,24–62 Both costs and
utilities were discounted at a rate of 3%/year.23
Cost-effectiveness was calculated using the incremental cost–
effectiveness ratio (ICER¼D Cost/D Effectiveness, where D Cost-
CostHNHDCostIHD and D Effectiveness¼ EffectivenessHNHD
EffectivenessIHD) and the net monetary benefit (NMB¼
(D Effectiveness l)D Costs, where l is the societal maximum
Table 2 | Variable baseline values and tested ranges for the pretransplant period from a decision analysis examining the
cost-effectiveness of HNDH
Primary analysis Monte Carlo analysis
Tested range Standard distribution
Variable Base Low High Mean Error Shape Sourcea
Transfer probabilities – annual
HNHD back to IHD 5% 0% 40% 5.0% 2.2% Beta Center
Death on dialysis
On transplant waiting list 6.3% 5% 8% 6.3% 2.4% Beta (10)
Not on waiting list 16.1% 12% 20% 16.1% 3.7% Beta (10)
Complication on dialysis
IHD 12.8% 3.1% 15.9% 12.8% 3.3% Beta (18, 19)
HNHD 3.1% 2.3% 12.8% 3.1% 1.7% Beta (18, 19)
Transfer probabilities – weekly
Death with dialysis complication 10% 5% 20% 5% 2.2% Beta Estimate
Resolution of dialysis complication 80% 50% 95% 80% 4% Beta Estimate
Annual costs (in thousands of 2003 Canadian dollars)
HNHD first year $107 $75 $140 $107 $3 Gamma (18, 19, 59)
HNHD postyear 1 $57 $40 $95 $57 $1 Gamma (18, 19, 59)
IHD $72 $54 $74 $72 $4 Gamma (18, 19, 21, 59)
Weekly costs (in thousands of 2003 Canadian dollars)
Complication on dialysis
IHD $7 $5 $9 $7 $2 Gamma (18, 19, 21, 59)
HNHD $4 53 $5 $4 $1 Gamma (18, 19, 21, 59)
Utilities
Complication on dialysis 0.30 0.10 0.50 0.30 0.04 Beta Estimate
HNHD 0.77 0.50 1.00 0.55 0.071 Beta (19, 45)
IHD 0.53 0.20 0.90 0.77 0.047 Beta (12, 19, 45)
Other
HNHD delay (weeks) 260 0 1040 104 26 Gamma Center
Center=data derived from study hospital; Estimate=values derived from author’s judgement.
aSource refers to the reference number from the references used as basis for the parameter estimate.
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willingness to pay for a QALY). As the value of l is unknown, we
investigated a broad range of possible values.
Modeled states
Figure 3 provides an overview of the health states studied in this
model. The model begins with patients initiating dialysis in the ‘Well
on Dialysis’ state. On a weekly basis, they could remain well, develop
a significant complication on dialysis, receive a live or deceased
donor renal transplant or die. A complication on dialysis was
defined as a nonfatal event requiring hospitalization for at least a
week, and transplantation was not allowed while such a complica-
tion was present. In the HNHD arm, the patient began on IHD and
could then transfer to HNHD. Subsequently, there was a chance of
failure of HNHD, with the return of the patient to IHD. All capital
costs for HNHD were borne in the first year.
We assumed that the graft functioned initially following
transplantation, but allowed for short- and long-term graft loss
with subsequent return of the patient to IHD. As a simplifying
assumption, we did not allow for a second transplant following graft
failure, as retransplantation is a relatively rare event,7 and this
exclusion is unlikely to significantly bias the results of the model.
The modeled costs for renal transplant were highest in the first post-
transplant year.12 Death could occur from any state.
Parameter value assignment
A literature review was conducted to determine the range and
distribution of likely values for parameters such as costs, utilities,
and transition probabilities. To account for variability in patient
populations and uncertainty and error in these estimates, the range
of each variable was based on available literature (Tables 2 and 3).
We based time to transplant, proportion of population eligible for
transplant, proportion of transplants from live donors and time to
HNHD on our hospital’s experience. One-way sensitivity analyses
were performed to test the robustness of the model across the
probable range of variables in the model (Tables 2 and 3). A second-
order Monte Carlo simulation was performed, where the model was
run 1000 times, each time randomly selecting a new value for all
uncertain variables from their likely distribution (Tables 2 and 3).
Table 3 | Variable baseline values and tested ranges for the post-transplant period from a decision analysis examining the
cost-effectiveness of HNDH
Primary analysis Monte carlo analysis
Tested range Standard distribution
Variable Bass Low High Mean Error Shape Sourcea
Transfer probabilities – annual
Post-transplant patient death rate (per year)
Live donor first year 2.0% 10.0% 10.0% 2.0% 0.2% Beta (7, 61–63)
Years 2–5 1.0% 1.5% 1.5% 1.0% 0.1% Beta (7, 61–63)
Years 5–10 2.0% 1.0% 1.0% 2.0% 0.2% Beta (7, 61–63)
Cadaveric donor first year 6.0% 11.0% 11.0% 6.0% 0.6% Beta (7, 6l–63)
Years 2–5 2.8% 3.0% 3.0% 2.8% 0.3% Beta (7, 6l–63)
Years 5–10 3.0% 2.4% 2.4% 3.0% 0.3% Beta (7, 61–63)
Post-transplant graft loss rate (per year)
Live donor first year 6.0% 5.0% 5.0% 6.0% 0.6% Beta (7, 61–63)
Years 2–5 1.8% 0.5% 0.8% 1.8% 0.18% Beta (7, 6l–63)
Years 5–10 1.0% 2.0% 2.0% 1.0% 0.10% Beta (7, 61–63)
Cadaveric donor first year 12.0% 10.0% 10.0% 12.0% 1.2% Beta (7, 6l–63)
Years 2–5 2.8% 4.3% 4.3% 2.8% 0.3% Beta (7, 6l–63)
Years 5–10 0.4% 0.6% 0.6% 0.4% 0.0% Beta (7, 6l–63)
Annual costs (in thousands of 2003 Canadian dollars)
Transplant year 1
Cadaveric donor $95 $70 $120 $95 $10 Gamma (12)
Live donor $103 $75 $130 $103 $10 Gamma (12)
Transplant subsequent years $40 $30 $50 $40 $4 Gamma (12)
Utilities
Working transplant utility 0.7 0.00 1.00 0.7 0.07 Beta (12)
Others
Time to transplant (yeans)
Live donor transplant 0.8 0 7 0.8 0.1 Gamma Center
Deceased donor 5 2 8 5 0.75 Gamma Center
Proportion
Eligible for transplant 50% 0% 100% 50% 20% Beta Estimate
From live donor 33% 0% 100% 33% 10% Beta Estimate
Discount rate (per year) 3.0% 2.5% 5.0% Estimate
Center=data derived from study hospital; Estimate=values derived from author’s judgement.
aSource refers to the reference number from the references used as basis for the parameter estimate.
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The estimated mortality rates while on dialysis were based on
registry data, and assumed a rate of 16.1% in dialysis patients who
were not on the transplant waiting list, and 6.3% for those who
were.10 Our dialysis mortality rate was calculated based on the
proportion of patients who were on the waiting listed. Mortality on
dialysis following graft failure is 9% lower than for those not eligible
for transplant.63 Following transplantation, weekly probabilities of
death, and graft loss between 0 and 1, 1 and 5, and beyond 5 years
were based on registry data assuming a linear rate change between
these time points.7,64–66
Reference case
Tables 2 and 3 list the variable values used in our reference case
scenario. Our reference case was based on a hypothetical cohort of
patients whose demographic characteristics matched the average
values from our previous studies (Table 4).18,19 The typical patient
in the reference case would be a 50-year-old man with relatively few
comorbidities (e.g. diabetes, coronary artery disease), and who has
been on dialysis for a long period of time. Based on the experience
of home hemodialysis patients at our center, we allowed half the
population to be eligible for transplantation, with 13 of grafts coming
from live donors. The time to transplant was 34 of a year for live
donors, and 5 years for deceased donor transplants. In addition, the
delay before initiation of HNHD was typically quite long (5 years).
Of note, the reference case cohort are generally younger, have been
on dialysis longer, more likely to be listed for transplant and have
fewer comorbidities than a ‘typical’ hemodialysis patient.7
Analysis
We analyzed model uncertainty using sensitivity analyses. For the
Monte Carlo simulation, we report the percentage of times that
HNHD was cost-effective relative to IHD (l¼ $50 000/QALY), and
a cost-effectiveness acceptability curve was created where the
probability that HNHD was cost-effective was calculated by
determining the percentage of iterations with an incremental cost/
QALY that was equal to or less than a series of cost–effectiveness
ceiling ratios (which represent the societal maximum willingness to
pay for a QALY, tested range $0–$100 000).67 To test the effect of
transplantation, we changed our model so that all patients in the
HNHD arm started on HNHD, with all patients in the scenario
eligible for a live donor transplant, and then varied the time to
transplantation.
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